Clinical trials in Oldenburg In Holstein – page 58

840 clinical trials in Oldenburg In Holstein, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in GermanyKlinischeStudien.de

Oldenburg In Holstein at a glance

840

clinical trials

Research sites1

Quick filters

840 trials in Oldenburg In Holstein

Open in trial search

Malignant melanoma+4

Not recruiting

Study on the Effectiveness and Safety of RO7198457 and Pembrolizumab for Patients with Untreated Advanced Melanoma

Registered drugNo placebo

Study on the Effectiveness and Safety of RO7198457 and Pembrolizumab for Patients with Untreated Advanced Melanoma

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Autogene Cevumeran
Sponsor:Genentech Inc.

Contact Research Centre

Squamous cell carcinoma of skin

Not recruiting

Study of mRNA-4157 and Pembrolizumab for Patients with Resectable Locally Advanced Cutaneous Squamous Cell Carcinoma

Registered drugNo placebo

Study of mRNA-4157 and Pembrolizumab for Patients with Resectable Locally Advanced Cutaneous Squamous Cell Carcinoma

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:MRNA-4157
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Hypercholesterolaemia

Not recruiting

Study Comparing Inclisiran and Bempedoic Acid for Lowering LDL Cholesterol in Patients with Atherosclerotic Cardiovascular Disease

Registered drugNo placebo

Study Comparing Inclisiran and Bempedoic Acid for Lowering LDL Cholesterol in Patients with Atherosclerotic Cardiovascular Disease

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Atorvastatin
Sponsor:Novartis Pharma GmbH

Contact Research Centre

Bronchiectasis

Not recruiting

Study on the Effects of Itepekimab for Patients with Non-Cystic Fibrosis Bronchiectasis

Investigational

Study on the Effects of Itepekimab for Patients with Non-Cystic Fibrosis Bronchiectasis

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:Itepekimab
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

Dermatitis atopic

Not recruiting

Study on Amlitelimab for Patients Aged 12 and Older with Moderate to Severe Atopic Dermatitis Using Topical Corticosteroids and Inadequate Response to Previous Treatments

Registered drug

Study on Amlitelimab for Patients Aged 12 and Older with Moderate to Severe Atopic Dermatitis Using Topical Corticosteroids and Inadequate Response to Previous Treatments

Registered drug

Germany

Participants:0–17 years · 18–64 years · 65+ years
Substances:Amlitelimab
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

Gastrointestinal melanoma+7

Not recruiting

Study of Encorafenib, Binimetinib, and Pembrolizumab for Patients with Advanced Melanoma with BRAF V600E/K Mutation

Registered drug

Study of Encorafenib, Binimetinib, and Pembrolizumab for Patients with Advanced Melanoma with BRAF V600E/K Mutation

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Binimetinib
Sponsor:Pfizer Inc.

Contact Research Centre

Chronic cutaneous lupus erythematosus

Not recruiting

Study of daxdilimab injection for adults with moderate to severe discoid lupus erythematosus

Investigational

Study of daxdilimab injection for adults with moderate to severe discoid lupus erythematosus

Investigational

Germany

Participants:18–64 years · 65+ years
Sponsor:Horizon Therapeutics Ireland Designated Activity Company

Contact Research Centre

Post-acute COVID-19 syndrome

Not recruiting

Study on the Effects of Vidofludimus Calcium for Patients with Post-COVID Syndrome

Investigational

Study on the Effects of Vidofludimus Calcium for Patients with Post-COVID Syndrome

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:Vidofludimus Calcium
Sponsor:Goethe University Frankfurt

Contact Research Centre

Chronic lymphocytic leukaemia

Not recruiting

Study on Bendamustine, Obinutuzumab, Zanubrutinib, and Venetoclax for Patients with Relapsed Chronic Lymphocytic Leukemia

Registered drugNo placebo

Study on Bendamustine, Obinutuzumab, Zanubrutinib, and Venetoclax for Patients with Relapsed Chronic Lymphocytic Leukemia

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Obinutuzumab
Sponsor:University Of Cologne

Contact Research Centre

B-cell lymphoma+2

Not recruiting

Study on Lisocabtagene Maraleucel for Adults with Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma

InvestigationalNo placebo

Study on Lisocabtagene Maraleucel for Adults with Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma

InvestigationalNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Lisocabtagene Maraleucel
Sponsor:Celgene Corp.

Contact Research Centre

Hidradenitis

Not recruiting

Study on Long-Term Use of Spesolimab for Patients with Hidradenitis Suppurativa Who Completed a Previous Spesolimab Study

Investigational

Study on Long-Term Use of Spesolimab for Patients with Hidradenitis Suppurativa Who Completed a Previous Spesolimab Study

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:Spesolimab
Sponsor:Boehringer Ingelheim Espana S.A.

Contact Research Centre

Non-small cell lung cancer

Not recruiting

Study of Datopotamab Deruxtecan, Durvalumab, and Carboplatin for Advanced Non-Small Cell Lung Cancer in Patients Without Actionable Genomic Alterations

Registered drugNo placebo

Study of Datopotamab Deruxtecan, Durvalumab, and Carboplatin for Advanced Non-Small Cell Lung Cancer in Patients Without Actionable Genomic Alterations

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:AstraZeneca AB

Contact Research Centre

Other cities in Germany

The busiest research cities in the country

All 504 cities in Germany

Clinical research in Oldenburg In Holstein

What the registry says about research in the country

01 Metabolic Disorders

Innovative clinical trials focusing on Type 2 Diabetes management and treatments, including studies of novel weekly insulin alternatives and oral medications for glycemic control.

Glycemic Control Studies
Insulin Alternatives Research
Cardiovascular Outcomes

Multiple studies evaluating new therapeutic approaches for better diabetes management and reducing cardiovascular risks.

02 Weight Management

Comprehensive research into obesity treatment and weight-related conditions, examining new therapeutic combinations and their effects on weight loss and associated health conditions.

Weight Loss Interventions
Obesity Medications
Comorbidity Management

Studies focusing on innovative approaches to weight management and treating obesity-related health complications.

03 Cardiovascular Health

Research examining treatments for atherosclerotic cardiovascular disease and related conditions, with emphasis on preventing major adverse cardiovascular events.

Cardiovascular Risk Reduction
Lipid Management
Preventive Therapies

Trials evaluating new medications for improving cardiovascular outcomes in high-risk patients.

04 Gastrointestinal Studies

Clinical investigations of treatments for Crohn's Disease and other digestive conditions, focusing on long-term efficacy and safety of new therapeutic approaches.

Inflammatory Bowel Disease
Long-term Treatment Outcomes
Disease Management

Studies aimed at improving quality of life for patients with chronic gastrointestinal conditions.

05 Oncology Research

Advanced studies in colorectal cancer treatment and management, including innovative approaches to Stage II and III cancer therapy.

Cancer Treatment Protocols
Disease-Free Survival
Adjuvant Therapy

Trials evaluating new treatment strategies for improving outcomes in cancer patients.

Back to Germany All countries